483
Livzon New North River Pharmaceutical Co., Ltd.Livzon New North River Pharmaceutical Co., Ltd. – FDA 483, Dec 20, 2024
Record Details
An FDA inspection of Livzon New North River Pharmaceutical Co., Ltd. identified significant deficiencies within its Quality Unit. The firm failed to adequately review and approve complete method validations for final product release, stability testing, and raw materials, and did not ensure appropriate testing of materials, particularly recovery solvents. Furthermore, the Quality Unit failed to investigate critical deviations related to retrospective analyses of method validations.
- Inspection date
- December 20, 2024
- Product type
- drugs
View Company Profile
ID · ad45afaf-9645-4f94-9c36-610869947a38
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.